Shield Therapeutics plc
STX.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | £32,292 | £21,116 | £14,077 | £49,727 |
| - Cash | £10,814 | £5,608 | £6,407 | £10,941 |
| + Debt | £27,048 | £21,056 | £15,799 | £15,881 |
| Enterprise Value | £48,526 | £36,563 | £23,469 | £54,666 |
| Revenue | £16,540 | £15,531 | £9,592 | £6,984 |
| % Growth | 6.5% | 61.9% | 37.3% | – |
| Gross Profit | £7,619 | £6,700 | £4,315 | £982 |
| % Margin | 46.1% | 43.1% | 45% | 14.1% |
| EBITDA | -£3,790 | -£6,142 | -£10,479 | -£15,638 |
| % Margin | -22.9% | -39.5% | -109.2% | -223.9% |
| Net Income | -£7,353 | -£9,067 | -£12,238 | -£16,511 |
| % Margin | -44.5% | -58.4% | -127.6% | -236.4% |
| EPS Diluted | -0.007 | -0.012 | -0.016 | -0.022 |
| % Growth | 38.8% | 25.6% | 29.7% | – |
| Operating Cash Flow | -£4,495 | -£3,660 | -£3,276 | -£13,836 |
| Capital Expenditures | -£0 | -£0 | -£800 | -£1,020 |
| Free Cash Flow | -£4,495 | -£3,660 | -£4,077 | -£14,855 |